19IN - Molecular targeted, systemic therapies for meningiomas

Date 28 September 2014
Event ESMO 2014
Session Current concepts and future avenues in meningioma
Topics Anticancer Agents
Central Nervous System Malignancies
Pathology/Molecular Biology
Basic Scientific Principles
Biological Therapy
Presenter Matthias Preusser
Citation Annals of Oncology (2014) 25 (suppl_4): iv8-iv8. 10.1093/annonc/mdu293
Authors M. Preusser
  • Department Of Medicine I, Vienna General Hospital (AKH) - Medizinische Universität Wien, 1090 - Vienna/AT




Standard treatments for meningiomas comprise surgical resection and radiotherapy. In the recurrent setting after exhaustion of all local treatment options no effective therapies are known and several drugs failed to show efficacy. Novel compounds may offer hope for better disease control. Upregulation of pro-angiogenic molecules and dysregulatoin of some signaling cascades such as mTor and PDGFR pathways are recurrently found in meningiomas. Furthermore, some evidence indicates that trabectedin may be an effective therapy for high-grade meningioma and a prospective trial is underway. Recent phase II trials investigating sunitinib pasireotide LAR and vatalinib have been completed. Still, there is a lack of conclusive clinical trials on medical therapy of meningioma. There remains a significant need for more basic investigations and clinical trials in meningioma. Promising novel therapeutics include antiangiogenic agents, molecular inhibitors of signaling cascades and trabectedin.


The author has declared no conflicts of interest.